ARCH Venture Management LLC Has $1.07 Million Stock Position in Singular Genomics Systems, Inc. (NASDAQ:OMIC)

ARCH Venture Management LLC reduced its holdings in shares of Singular Genomics Systems, Inc. (NASDAQ:OMIC) by 96.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 126,630 shares of the company’s stock after selling 3,672,296 shares during the quarter. Singular Genomics Systems makes up about 0.4% of ARCH Venture Management LLC’s holdings, making the stock its 9th largest position. ARCH Venture Management LLC owned about 5.13% of Singular Genomics Systems worth $1,070,000 at the end of the most recent quarter.

Singular Genomics Systems Stock Down 3.0 %

OMIC stock opened at $15.76 on Thursday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.04 and a current ratio of 8.77. The company has a market capitalization of $38.88 million, a price-to-earnings ratio of -0.40 and a beta of 1.34. Singular Genomics Systems, Inc. has a fifty-two week low of $5.34 and a fifty-two week high of $19.80. The stock has a fifty day moving average of $8.58 and a 200-day moving average of $10.67.

Singular Genomics Systems (NASDAQ:OMIC) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($8.57) EPS for the quarter, topping the consensus estimate of ($8.86) by $0.29. Singular Genomics Systems had a negative net margin of 3,375.72% and a negative return on equity of 54.66%. The company had revenue of $0.74 million during the quarter, compared to the consensus estimate of $0.40 million.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group lowered their price objective on shares of Singular Genomics Systems from $22.50 to $6.50 and set a “neutral” rating on the stock in a research report on Tuesday, July 9th.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.